SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Anuh Pharma - Quaterly Results

08 Nov 2025 Evaluate
The revenue for the September 2025 quarter is pegged at Rs. 1858.83 millions, about 12.01% up against Rs. 1659.54 millions recorded during the year-ago period.The Net Profit of the company slipped to Rs. 76.11 millions from Rs. 150.43 millions, a decline of -49.41% on QoQ basis.Operating profit for the quarter ended September 2025 decreased to 128.57 millions as compared to 202.80 millions of corresponding quarter ended September 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 1858.83 1659.54 12.01 3723.62 3038.62 22.54 6615.15 6470.04 2.24
Other Income 9.78 34.00 -71.24 43.66 71.19 -38.67 94.55 120.98 -21.85
PBIDT 128.57 202.80 -36.60 265.36 345.67 -23.23 703.64 872.47 -19.35
Interest 0.76 1.64 -53.66 2.87 3.06 -6.21 6.19 3.54 74.86
PBDT 127.81 201.16 -36.46 262.49 342.61 -23.39 697.45 868.93 -19.73
Depreciation 28.62 19.22 48.91 53.77 38.02 41.43 87.39 85.84 1.81
PBT 99.19 181.94 -45.48 208.72 304.59 -31.48 610.06 783.09 -22.10
TAX 23.08 31.51 -26.75 49.60 59.08 -16.05 136.53 182.52 -25.20
Deferred Tax -4.92 -8.39 -41.36 -3.30 -8.02 -58.85 -16.52 3.59 -560.17
PAT 76.11 150.43 -49.41 159.12 245.51 -35.19 473.53 600.57 -21.15
Equity 501.12 250.56 100.00 501.12 250.56 100.00 250.56 250.56 0.00
PBIDTM(%) 6.92 12.22 -43.40 7.13 11.38 -37.36 10.64 13.48 -21.12

Anuh Pharma Share Price

78.67 -0.57 (-0.72%)
13-Apr-2026 14:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1660.10
Dr. Reddys Lab 1232.05
Cipla 1212.00
Zydus Lifesciences 924.70
Lupin 2323.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×